Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis evidence on ‘step change’ Jakavi not yet enough for NICE

This article was originally published in Scrip

Executive Summary

Novartis has so far failed to convince NICE, the health technology appraisal institute, to recommend for use on the National Health Service the firm's JAK inhibitor, Jakavi (ruxolitinib). Even though the institute recognized that Jakavi was an innovative treatment for patients with splenomegaly and myelofibrosis, there were uncertainties in the evidence, including missing data, according to draft guidance issued on 13 February. That means that a second appraisal committee must now take place on 13 March. Carole Longson, director of NICE's Health Technology Evaluation Centre urged "all those with an interest in myelofibrosis" to comment via the NICE website.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts